

RECEIVED
CENTRAL FAX CENTER


JAN 05 2007

USSN: 10/523,337
Group Art Unit 1626
Docket No.: 198P00812USWO

Claims:

1 - 10. (Cancelled)

11. (Currently Amended) The compound of claim 34 represented by the formula:



wherein

R_{11} is selected from the group consisting of C_5 - C_{12} alkyl, C_5 - C_{12} alkoxy, C_5 - C_{12} alkenyl, and C_5 - C_{12} alkynyl;

R_7 and R_8 are independently selected from the group consisting of O, S, CHR_{26} , CHR_{26} , NR_{26} , and N;


wherein R_{26} is H, F or C_1 - C_4 alkyl;

R_{25} is N or CH ;

R_2 is NH_2 ;

R_3 is selected from the group consisting of H, C_1 - C_4 alkyl, $(C_1$ - C_4 alkyl)OH, and $(C_1$ - C_4 alkyl) NH_2 ;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein X and R_{12} are independently selected from the group consisting of O and S;

R_{23} is selected from the group consisting of H, F, OH, C_1 - C_4 alkyl, CO_2H and C_1 - C_4 alkyl;


R_{24} is selected from the group consisting of H, F, C_1 - C_4 alkyl and PO_3H_2 , or R_{23} together with R_{24} and the carbon to which they are attached form a carbonyl group; and

USSN: 10/523,337
Group Art Unit 1626
Docket No.: 198P00812USWO

y and m are integers independently ranging from 0 to 4;
or a pharmaceutically acceptable salt or tautomer thereof.


12. (Original) The compound of claim 11 wherein
m is 0;
y is 0 or 1;
R₂₅ is CH;
R₂₃ is H or F; and
R₂₄ is selected from the group consisting of H, F and C₁-C₄ alkyl.
13. (Original) The compound of claim 11 wherein R₃ is selected from the group consisting of C₁-C₃ alkyl and (C₁-C₄ alkyl)OH.
14. (Original) The compound of claim 12 or 13 wherein
R₇ is NH; and
X is O;
or a pharmaceutically acceptable salt or tautomer thereof.
15. (Original) The compound of claim 14 wherein
y is 0; and
R₁₅ is OH.
16. (Previously Presented) The compound of claim 13 represented by the formula:

USSN: 10/523,337
 Group Art Unit 1626
 Docket No.: 198P00812USWO



wherein R_{11} is C_5 - C_{18} alkyl, C_5 - C_{12} alkoxy, or C_5 - C_{18} alkenyl; and
 R_8 is N;
 or a pharmaceutically acceptable salt or tautomer thereof.

17. (Original) The compound of claim 16 wherein R_{15} is selected from the group consisting of hydroxy and




wherein R_{12} is O or S;
 or a pharmaceutically acceptable salt or tautomer thereof.

18. (Original) The compound of claim 17 wherein R_{11} is C_5 - C_9 alkyl;
 R_{15} is OH and
 R_3 is selected from the group consisting of CH_3 , CH_2CH_3 , CH_2OH , CH_2CH_2OH
 and $CH_2CH_2CH_2OH$.

USSN: 10/523,337
 Group Art Unit 1626
 Docket No.: 198P00812USWO

19. (Previously Presented) A composition comprising a compound of claim 34, 11 or 16 and a pharmaceutically acceptable carrier.
20. (Currently Amended) A pharmaceutical composition comprising a compound represented by the formula:




wherein R_{11} is C_5 - C_{18} alkyl C_5 - C_{12} alkoxy or C_5 - C_{18} alkenyl;

Q is imidazolyl ~~selected from the group consisting of C_2 - C_6 optionally substituted cycloalkyl, C_2 - C_6 optionally substituted heterocyclic, C_3 - C_6 optionally substituted aryl, C_3 - C_6 optionally substituted heteroaryl and $NH(CO)$;~~

R_3 is selected from the group consisting of H, C_1 - C_4 alkyl and $(C_1$ - C_4 alkyl)OH;

R_{23} is H or C_1 - C_4 alkyl, and

R_{15} is selected from the group consisting of hydroxy, phosphonate, and




wherein X and R_{12} are independently selected from the group consisting of O and S;

or a pharmaceutically acceptable salt or tautomer thereof and a pharmaceutically acceptable carrier.

21. (Cancelled)

USSN: 10/523,337
 Group Art Unit 1626
 Docket No.: 198P00812USWO


22. (Previously Presented) The composition of claim 38 wherein R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S.

23 - 27. (Cancelled)

28. (Currently Amended) A method of promoting wound healing in a warm blooded vertebrate, said method comprising the step of administering a composition comprising a compound of the general structure:




wherein R_{11} is C_5 - C_{18} alkyl, C_5 - C_{12} alkoxy, or C_5 - C_{18} alkenyl;

Q is ~~imidazolyl selected from the group consisting of C_3 - C_6 optionally substituted cycloalkyl, C_3 - C_6 optionally substituted heterocyclic, C_3 - C_6 optionally substituted aryl, C_3 - C_6 optionally substituted heteroaryl and $\text{NH}(\text{CO})$;~~

R_3 is selected from the group consisting of H, C_1 - C_4 alkyl and $(C_1$ - C_4 alkyl)OH;

R_{23} is H or C_1 - C_4 alkyl, and

R_{15} is selected from the group consisting of hydroxy, phosphonate, and




USSN: 10/523,337
 Group Art Unit 1626
 Docket No.: 198P00812USWO

wherein X and R₁₂ are independently selected from the group consisting of O and S;
 or a pharmaceutically acceptable salt or tautomer thereof.

29 - 33. (Cancelled)

34. (Currently Amended) A compound represented by the formula:



wherein

R₁₁ is selected from the group consisting of C₅-C₁₂ alkyl, C₅-C₁₂ alkenyl, C₅-C₁₂ alkynyl, C₅-C₁₂ alkoxy, (CH₂)_pO(CH₂)_q, C₅-C₁₀ (aryl)R₂₀, C₅-C₁₀ (heteroaryl)R₂₀, C₅-C₁₀ (cycloalkyl)R₂₀, C₅-C₁₀ alkoxy(aryl)R₂₀, C₅-C₁₀ alkoxy(heteroaryl)R₂₀ and C₅-C₁₀ alkoxy(cycloalkyl)R₂₀;

wherein R₂₀ is H or C₁-C₁₀ alkyl;

R₂₉ is H or halo;

R₂ is NH₂;

R₃ is selected from the group consisting of H, C₁-C₆ alkyl, (C₁-C₄ alkyl)OH, and (C₁-C₄ alkyl)NH₂;

R₂₃ is selected from the group consisting of H, F, NH₂, OH, CO₂H, C₁-C₆ alkyl, (C₁-C₄ alkyl)OH, and (C₁-C₄ alkyl)NH₂;

R₂₄ is selected from the group consisting of H, F and PO₃H₂, or R₂₃ together with R₂₄ and the carbon to which they are attached form a carbonyl group;


USSN: 10/523,337
 Group Art Unit 1626
 Docket No.: 198P00812USWO

R_{25} , R_7 , and R_8 are independently selected from the group consisting of O, S,
~~CHR₂₆~~, ~~CR₂₆~~, NR₂₆, and N;

R_{25} is CHR₂₆;

wherein R_{26} is H, F or C₁-C₄ alkyl;

R_{15} is selected from the group consisting of hydroxy, phosphonate, and



wherein R_{12} is selected from the group consisting of O, NH and S;

X is selected from the group consisting of O, NH and S;


y and m are integers independently ranging from 0 to 4;

p and q are integers independently ranging from 1 to 10;

or a pharmaceutically acceptable salt or tautomer thereof.

35 - 43 (Cancelled)

44. (New) The method of claim 28 wherein R_{15} is selected from the group consisting of hydroxy and



wherein R_{12} is O or S.

45. (New) The method of claim 44 wherein R_{15} is OH or a pharmaceutically acceptable salt or tautomer thereof.